DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Acne” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the Acne market, comprising key
pipeline and marketed drugs, clinical trials, upcoming and regulatory
events, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts
Key Takeaways
-
The report estimates that in 2017, there were approximately 624
million prevalent cases of acne worldwide, and forecasts that number
to increase to 683 million prevalent cases by 2026. -
Approved drugs in the acne space focus on a wide variety of targets.
These drugs are commonly administered via the oral and topical routes. -
The majority of industry-sponsored drugs in active clinical
development for acne are in Phase II, with one drug in the NDA/BLA
phase. -
Therapies in mid-to-late-stage development for acne focus on a wide
variety of targets. The majority of the pipeline drugs are
administered via the topical route, with the remainder being oral,
subcutaneous, intranasal, or intravenous formulations. -
High-impact upcoming events for drugs in the acne space comprise
topline Phase II trial results for BTX-1503 and VB 1953, topline Phase
III trial results for Winlevi/Breezula and TWIN, and an estimated
PDUFA date for FMX101. -
The overall likelihood of approval of a Phase I dermatology-general
asset is 28.0%, and the average probability a drug advances from Phase
III is 72.4%. Drugs, on average, take 7.8 years from Phase I to
approval in both the dermatology-general space and the overall
dermatology space. -
There have been 21 licensing and asset acquisition deals involving
acne drugs during 2014-19, seven of which occurred in 2014. The
largest deal was the $650m agreement in 2018 between Almirall and
Allergan for the acquisition of a portfolio of five products from
Allergan’s Medical Dermatology unit in the US, which comprises of
mature and growth brands Aczone (dapsone), Tazorac (tazarotene),
Azelex (azelaic acid), Cordran Tape (fludroxycortide), and Seysara
(sarecycline). -
The distribution of clinical trials across Phase I-IV indicates that
the majority of trials for acne have been in the late phases of
development, with 53% of trials in Phase III-IV, and 47% in Phase I-II. -
The US has a substantial lead in the number of acne clinical trials
globally. Germany leads the major EU markets, while Japan has the top
spot in Asia. -
Clinical trial activity in the acne space is dominated by completed
trials. GlaxoSmithKline has the highest number of completed clinical
trials for acne, with 35 trials. -
GlaxoSmithKline leads industry sponsors with by far the highest number
of clinical trials for acne, followed by Allergan
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
TREATMENT
Topical therapy
Systemic therapy
Physical treatments
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
FMX101 for Acne (September 11, 2018)
Winlevi / Breezula for Acne (July 10, 2018)
Olumacostat Glasaretil for Acne (March 5, 2018)
Ammonia Oxidizing Bacteria for Acne (October 19, 2017)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Foamix Submits First Topical Minocycline For Acne
Differin Extends With Cleanser, Moisturizer, Biore Adds Foam In OTC Skin
Care
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/9vkn0i
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Dermatology